Keyword Search
Legend:
CC = Colorado Convention Center H = Hyatt Regency Denver at Colorado Convention Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Adaptive Design returned 41 record(s)
|
|
Sunday, 07/28/2019
|
A Case Study of Phase II/III Seamless Adaptive Design
Hui Quan, Sanofi US; Yi Xu, Sanofi; Yixin Chen, Sanofi; Lei Gao, Vertex Pharmaceuticals; Xun Chen, Sanofi
2:05 PM
|
Bayesian Adaptive Approach for Neoadjuvant/Adjuvant Oncology Trial
Jing Zhao, Merck Research Labs
2:25 PM
|
Sample Size Re-Estimation in Action: Design Consideration, Charter Development, and Implementation of Analyzes in a Trial with Survival Endpoints
Adam Hamm, Cytel, Inc.
2:45 PM
|
Similarity-Based Artificial Intelligence for Adaptive Clinical Trial and Beyond
Mark Chang, Veristat; Susan Hwang, Boston University
3:05 PM
|
Bayesian Dose-Finding Model with Adaptive Time-To-Event Weight Incorporating Cycle Information for Immuno-Oncology Studies
Zhaowei Hua, Alnylam Pharmaceuticals, Inc.; Yutong Li, University of Illinois at Urbana-Champaign; Ying Yuan, Takeda Pharmaceutical Company Ltd ; Dan Zhao, Takeda Pharmaceutical Company Ltd
3:20 PM
|
Incorporating Auxiliary Data to Improve Conditional Power Estimation
Jian Zhu, Takeda Pharmaceuticals; Xin Li, George Washington University; Godwin Yung, Takeda Pharmaceuticals; Jianchang Lin, Takeda Pharmaceuticals
4:20 PM
|
A Practical Perspective: Application of the Generalized Approach for Adaptive Design
Jin Wang, Abbott Vascular; juanjuan li, abbott; Yu Shu, Abbott; xiaolu su, abbott
4:35 PM
|
Group-Sequential Randomized Trial Design Utilizing the MEM Framework for Incorporating Historical Data
Ales Kotalik, University of Minnesota; David Michael Vock, University of Minnesota; Joseph Koopmeiners, University of Minnesota
4:35 PM
|
|
Monday, 07/29/2019
|
Adaptive Design with Biomarker Population Deselection and Enrichment for Oncology Trials
Pingye Zhang; Yue Shentu, Merck & Co., Inc.; Qi Liu, Merck & Co., Inc.
|
SMART for Health App Recommenders
Ying Kuen Ken Cheung, Columbia University
8:35 AM
|
Optimal Selection Procedures and Adaptive Designs for Seamless Phase 2/3 Clinical Trials
Vladimir Dragalin, Janssen R&D
8:35 AM
|
Adaptive Design with Biomarker Population Deselection and Enrichment for Oncology Trials
Pingye Zhang; Yue Shentu, Merck & Co., Inc.; Qi Liu, Merck & Co., Inc.
9:20 AM
|
Bayesian Models for Precision Oncology Clinical Trials
Peter Müller, University of Texas Austin; Yanxun Xu, Johns Hopkins University; Don Berry, MDACC; Apostolia Tsimberidou, MDACC
9:35 AM
|
Dynamic Data Monitoring for On-Going Clinical Trials
Tai Xie, Brightech International; Ping Gao, Brightech International; Peng Zhang, Brightech International; Yue Tu, Brightech International; Joe Shih, Rutgers University
9:50 AM
|
Adaptive Designs for Learning Optimal Individualized Treatment Rules
Mark van der Laan, UC Berkeley
10:35 AM
|
How the 2018 FDA Adaptive Design Draft Guidance Can Help to Increase the Use of Adaptive Designs in Industry
David Manner, Eli Lilly & Company
10:35 AM
|
Points to Consider in the Design of Adaptive Platform Clinical Trials in Non-Alcoholic Steatohepatitis
Peter Mesenbrink, Novartis Pharmaceuticals
11:35 AM
|
Adaptive Design and Analysis of Multi-Reader Multi-Case Studies
Weijie Chen, Food and Drug Administration; Zhipeng Huang, FDA/CDER; Frank Samuelson, FDA/CDRH; Lucas Tcheuko, FDA/CTP
3:05 PM
|
|
Tuesday, 07/30/2019
|
Comparison of Parameter Estimates from Optimal Dynamic Treatment Rule-Based Adaptive Designs
Lina Montoya, University of California, Berkeley; James Roose, University of California, Berkeley; Mark van der Laan, UC Berkeley
|
A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Quasi-Continuous Toxicity Index
Sungjin Kim, Cedars-Sinai Medical Center; Zahra Razaee, Cedars-Sinai Medical Center; Andre Rogatko, Cedars-Sinai Medical Center; Mourad Tighiouart, Cedars-Sinai Medical Center
|
Less Is More – Adaptive Seamless Phase II/III Design
Helen Chen, GSK; Jonathan Haddad , GlaxoSmithKline; Xiaowei Wang, GlaxoSmithKline
|
Blinding in Open Label Study with Adaptive Design
Bo Xu, Boston Biomedical Inc; Bo Jin, Boston Biomedical Inc; Alex Dmitrienko, Mediana Inc
|
Criteria for Choosing a Futility Method for Clinical Studies
Richard McNally, Covance-Chiltern
|
Quantifying the Number of Events Borrowed from External Data in Hybrid Control Arms
Brian Segal, Flatiron Health; Carrie Bennette, Flatiron Health; Somnath Sarkar, Flatiron Health
|
Adapting Data Collection Activities Using Survey Fielding Metrics
A. Elizabeth Ormson, NORC at the University of Chicago; Rupa Datta, NORC at the University of Chicago; Weihuang Wong, NORC at the University of Chicago
10:35 AM
|
Responsive and Adaptive Survey Design: Use of Bias Propensity During Data Collection to Reduce Nonresponse Bias
Daniel Pratt, RTI International; Andrey Peytchev, RTI International; Michael Duprey, RTI International
10:55 AM
|
Blinding in Open Label Study with Adaptive Design
Bo Xu, Boston Biomedical Inc; Bo Jin, Boston Biomedical Inc; Alex Dmitrienko, Mediana Inc
10:55 AM
|
Criteria for Choosing a Futility Method for Clinical Studies
Richard McNally, Covance-Chiltern
11:10 AM
|
Time-To-Event Bayesian Optimal Interval Design to Accelerate Dose-Finding Based on Both Efficacy and Toxicity Outcomes
Kentaro Takeda, Astellas Pharma Global Development, Inc.
11:15 AM
|
Dynamic Interventions for Outcome Improvement: Minimizing Cost for a Fixed RMSE
Stephanie M Coffey, U.S. Census Bureau
11:15 AM
|
Evaluation of Type 1 Error in a 2-In-1 Adaptive Phase 2/3 Design with Dual-Primary Endpoints in Oncology Studies
Li Fan, Merck; Jing Zhao, Merck Research Labs
11:20 AM
|
Quantifying the Number of Events Borrowed from External Data in Hybrid Control Arms
Brian Segal, Flatiron Health; Carrie Bennette, Flatiron Health; Somnath Sarkar, Flatiron Health
11:35 AM
|
Developing Innovative Group Sequential Design Trials That Account for the Correlation Between Test Statistics
JonDavid Sparks, Eli Lilly & Company; Bill Prucka, Eli Lilly & Company; Brian Millen, Eli Lilly & Company
11:50 AM
|
|
Wednesday, 07/31/2019
|
Optimal Surrogate in Targeted Adaptive Sequential Trials
Ivana Malenica, U.C. Berkeley; Mark van der Laan, UC Berkeley
|
The Research and Methodology on Staggering the 2020 Census Mailings
Ioana (Julia) Marasteanu, U.S Census Bureau; Sarah Konya, U.S. Census Bureau
8:35 AM
|
BayesCT: a Tool for Simulation and Analysis of Adaptive Bayesian Clinical Trials
Thevaa Chandereng, University of Wisconsin-Madison; Donald Musgrave, Medtronic; Tarek Haddad, Medtronic ; Graeme Hickey, Medtronic; Tim Hanson, Medtronic ; Theodore Lystig, Medtronic; Rick Chappell, University of Wisconsin-Madison
9:50 AM
|
Adaptive Designs for Drug Combination Informed by Longitudinal Model for the Response
Tobias Mielke, Janssen
11:05 AM
|
Phase 1/2 Seamless Design
Inna Perevozskaya, GSK; Rosemary Schroyer, GSK; Helen Chen, GSK
11:35 AM
|
Adjusting for Bias Induced by Informative Adaptive Designs
Nancy Flournoy, University of Missouri; Assaf P Oron, Institute for Disease Modeling
2:55 PM
|
|
|
